Nautilus Biotechnology (NAUT) Cash from Financing Activities (2020 - 2026)

Nautilus Biotechnology has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $1.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $1.1 million, up 6038.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 41.88% YoY), and the FY2025 annual result was $214000.0, down 81.29% from the prior year.
• Cash from Financing Activities came in at $1.1 million for Q1 2026 at Nautilus Biotechnology, up from $101000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.1 million in Q1 2026 to a low of $1000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $137500.0 (2022), against an average of $212062.5.
• Across the five-year window, Cash from Financing Activities tumbled 99.94% in 2022 and soared 24400.0% in 2024, its largest moves.
• Nautilus Biotechnology's Cash from Financing Activities stood at $135000.0 in 2022, then jumped by 87.41% to $253000.0 in 2023, then surged by 73.91% to $440000.0 in 2024, then sank by 77.05% to $101000.0 in 2025, then surged by 994.06% to $1.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.1 million (Q1 2026), $101000.0 (Q4 2025), and $95000.0 (Q2 2025), per Business Quant data.